Leerink Partnrs Comments on Lexicon Pharmaceuticals, Inc.’s FY2027 Earnings (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Equities research analysts at Leerink Partnrs upped their FY2027 earnings estimates for Lexicon Pharmaceuticals in a report released on Friday, May 3rd. Leerink Partnrs analyst R. Ruiz now expects that the biopharmaceutical company will post earnings per share of $0.10 for the year, up from their previous estimate of $0.07. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.66) per share.

Several other analysts also recently issued reports on the stock. SVB Leerink began coverage on shares of Lexicon Pharmaceuticals in a research report on Tuesday, April 30th. They issued an “outperform” rating and a $5.00 price objective for the company. StockNews.com upgraded shares of Lexicon Pharmaceuticals to a “sell” rating in a report on Wednesday, May 1st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Friday.

Lexicon Pharmaceuticals Price Performance

LXRX stock opened at $1.74 on Monday. The firm has a market cap of $428.46 million, a P/E ratio of -2.10 and a beta of 1.38. The company has a debt-to-equity ratio of 1.07, a quick ratio of 5.58 and a current ratio of 5.60. Lexicon Pharmaceuticals has a 1 year low of $0.92 and a 1 year high of $3.79. The stock has a 50-day simple moving average of $2.10 and a 200-day simple moving average of $1.75.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.03. The firm had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.68 million. Lexicon Pharmaceuticals had a negative return on equity of 137.53% and a negative net margin of 8,311.12%.

Institutional Trading of Lexicon Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC bought a new position in Lexicon Pharmaceuticals during the third quarter worth $64,000. Commonwealth Equity Services LLC boosted its holdings in shares of Lexicon Pharmaceuticals by 160.9% in the 3rd quarter. Commonwealth Equity Services LLC now owns 39,569 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 24,400 shares during the period. TIAA Trust National Association bought a new stake in shares of Lexicon Pharmaceuticals during the 3rd quarter valued at about $29,000. Swiss National Bank raised its stake in Lexicon Pharmaceuticals by 4.4% during the third quarter. Swiss National Bank now owns 242,300 shares of the biopharmaceutical company’s stock worth $264,000 after acquiring an additional 10,300 shares during the period. Finally, KWB Wealth bought a new position in Lexicon Pharmaceuticals in the fourth quarter worth about $62,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.